R&D Directions

Research and development directions

GDNF Mimetics directly builds upon scientific novelty and innovativeness of the R&D work planned. The small molecule developed by GeneCode is the first agent that has ability of neuroprotection and neurorestotation targeting through GDNF receptors GFRα1/RET. Existing drugs are generic and have very similar treatment paths. The GeneCode drug is the first one that might have potential to protect and regenerate the neurons, and reduce inflammation in ALS, IBD, PD and RP patients. GDNF mimetics application does not involve any surgical procedures as the drug will be administered orally or systemically. Therefore, the uniqueness of the GeneCode drug is expected to result in significant improvement in the quality and duration of life of ALS, IBD, PD and RP patients.


Parkinson’s disease (PD)

Amyotrophic Lateral Sclerosis (ALS)

Inflammatory bowel disease (IBD)

Retinitis pigmentosa (RP)